Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Enterprise Value (2016 - 2026)

Integra Lifesciences Holdings' Enterprise Value history spans 17 years, with the latest figure at -$263.7 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 3.59% to -$263.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$263.7 million, a 3.59% increase, with the full-year FY2025 number at -$263.7 million, up 3.59% from a year prior.
  • Enterprise Value hit -$263.7 million in Q4 2025 for Integra Lifesciences Holdings, up from -$267.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for IART hit a ceiling of -$253.6 million in Q2 2025 and a floor of -$663.1 million in Q1 2024.
  • Historically, Enterprise Value has averaged -$369.1 million across 5 years, with a median of -$309.1 million in 2023.
  • Biggest five-year swings in Enterprise Value: tumbled 115.74% in 2024 and later soared 58.79% in 2025.
  • Tracing IART's Enterprise Value over 5 years: stood at -$513.4 million in 2021, then rose by 11.06% to -$456.7 million in 2022, then skyrocketed by 32.31% to -$309.1 million in 2023, then rose by 11.5% to -$273.6 million in 2024, then rose by 3.59% to -$263.7 million in 2025.
  • Business Quant data shows Enterprise Value for IART at -$263.7 million in Q4 2025, -$267.9 million in Q3 2025, and -$253.6 million in Q2 2025.